NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Mr. Douglas F. Kling

Chief Operating Officer

Dr. Sheng  Cui Ph.D.

Vice President & Head of Chemistry Manufacturing and Controls (CMC)

Mr. Jim  Jacobson

Chief Legal Officer & Secretary

Mr. William  Jones Jr., M.B.A.

Chief Commercial Officer

Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.

Founder, Chief Scientific Officer, Member of Executive Board & Director

Ms. Juliette  Audet M.B.A., M.Sc.

Chief Business Officer

Dr. Marc  Ditmarsch M.D.

Chief Development Officer

Mr. Mayur Amrat Somaiya

Chief Financial Officer

Ms. Annie  Neild

Vice President & Head of Regulatory Affairs

Dr. Michael Harvey Davidson FACC, Facp., M.D.

Chief Executive Officer, President, Executive Board Member & Director

Биотехнологии

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. Структура на управлението

Информация за управлението